Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 146

1.

Inositol polyphosphate 4-phosphatase type II regulation of androgen receptor activity.

Zhang M, Suarez E, Vasquez JL, Nathanson L, Peterson LE, Rajapakshe K, Basil P, Weigel NL, Coarfa C, Agoulnik IU.

Oncogene. 2019 Feb;38(7):1121-1135. doi: 10.1038/s41388-018-0498-3. Epub 2018 Sep 18.

2.

Targeting the Hsp40/Hsp70 Chaperone Axis as a Novel Strategy to Treat Castration-Resistant Prostate Cancer.

Moses MA, Kim YS, Rivera-Marquez GM, Oshima N, Watson MJ, Beebe KE, Wells C, Lee S, Zuehlke AD, Shao H, Bingman WE 3rd, Kumar V, Malhotra SV, Weigel NL, Gestwicki JE, Trepel JB, Neckers LM.

Cancer Res. 2018 Jul 15;78(14):4022-4035. doi: 10.1158/0008-5472.CAN-17-3728. Epub 2018 May 15.

3.

Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting.

Luo J, Attard G, Balk SP, Bevan C, Burnstein K, Cato L, Cherkasov A, De Bono JS, Dong Y, Gao AC, Gleave M, Heemers H, Kanayama M, Kittler R, Lang JM, Lee RJ, Logothetis CJ, Matusik R, Plymate S, Sawyers CL, Selth LA, Soule H, Tilley W, Weigel NL, Zoubeidi A, Dehm SM, Raj GV.

Eur Urol. 2018 May;73(5):715-723. doi: 10.1016/j.eururo.2017.11.038. Epub 2017 Dec 16. Review.

4.

Vitamin D receptor activation reduces VCaP xenograft tumor growth and counteracts ERG activity despite induction of TMPRSS2:ERG.

Roberts JM, Martin RS, Piyarathna DB, MacKrell JG, Rocha GV, Dodge JA, Coarfa C, Krishnan V, Rowley DR, Weigel NL.

Oncotarget. 2017 Jul 4;8(27):44447-44464. doi: 10.18632/oncotarget.17968.

5.

Inhibition of the hexosamine biosynthetic pathway promotes castration-resistant prostate cancer.

Kaushik AK, Shojaie A, Panzitt K, Sonavane R, Venghatakrishnan H, Manikkam M, Zaslavsky A, Putluri V, Vasu VT, Zhang Y, Khan AS, Lloyd S, Szafran AT, Dasgupta S, Bader DA, Stossi F, Li H, Samanta S, Cao X, Tsouko E, Huang S, Frigo DE, Chan L, Edwards DP, Kaipparettu BA, Mitsiades N, Weigel NL, Mancini M, McGuire SE, Mehra R, Ittmann MM, Chinnaiyan AM, Putluri N, Palapattu GS, Michailidis G, Sreekumar A.

Nat Commun. 2016 May 19;7:11612. doi: 10.1038/ncomms11612.

6.

Nuclear Receptor Corepressor 1 Expression and Output Declines with Prostate Cancer Progression.

Lopez SM, Agoulnik AI, Zhang M, Peterson LE, Suarez E, Gandarillas GA, Frolov A, Li R, Rajapakshe K, Coarfa C, Ittmann MM, Weigel NL, Agoulnik IU.

Clin Cancer Res. 2016 Aug 1;22(15):3937-49. doi: 10.1158/1078-0432.CCR-15-1983. Epub 2016 Mar 11.

7.

Differential Regulation of Progesterone Receptor-Mediated Transcription by CDK2 and DNA-PK.

Treviño LS, Bolt MJ, Grimm SL, Edwards DP, Mancini MA, Weigel NL.

Mol Endocrinol. 2016 Feb;30(2):158-72. doi: 10.1210/me.2015-1144. Epub 2015 Dec 11.

8.

Differential regulation of metabolic pathways by androgen receptor (AR) and its constitutively active splice variant, AR-V7, in prostate cancer cells.

Shafi AA, Putluri V, Arnold JM, Tsouko E, Maity S, Roberts JM, Coarfa C, Frigo DE, Putluri N, Sreekumar A, Weigel NL.

Oncotarget. 2015 Oct 13;6(31):31997-2012. doi: 10.18632/oncotarget.5585.

9.

Hormones and Cancer--Looking Forward.

Weigel NL.

Horm Cancer. 2015 Dec;6(5-6):189-90. doi: 10.1007/s12672-015-0234-1. Epub 2015 Aug 25. No abstract available.

PMID:
26305704
10.

Hormones and Cancer: an exciting young journal for an expanding field of basic, translational, and clinical study.

Weigel NL.

Horm Cancer. 2015 Jun;6(2-3):65-6. doi: 10.1007/s12672-015-0220-7. Epub 2015 Apr 14. No abstract available.

PMID:
25869229
11.

GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex.

He B, Lanz RB, Fiskus W, Geng C, Yi P, Hartig SM, Rajapakshe K, Shou J, Wei L, Shah SS, Foley C, Chew SA, Eedunuri VK, Bedoya DJ, Feng Q, Minami T, Mitsiades CS, Frolov A, Weigel NL, Hilsenbeck SG, Rosen DG, Palzkill T, Ittmann MM, Song Y, Coarfa C, O'Malley BW, Mitsiades N.

Proc Natl Acad Sci U S A. 2014 Dec 23;111(51):18261-6. doi: 10.1073/pnas.1421415111. Epub 2014 Dec 8.

12.

A role for site-specific phosphorylation of mouse progesterone receptor at serine 191 in vivo.

Grimm SL, Ward RD, Obr AE, Franco HL, Fernandez-Valdivia R, Kim JS, Roberts JM, Jeong JW, DeMayo FJ, Lydon JP, Edwards DP, Weigel NL.

Mol Endocrinol. 2014 Dec;28(12):2025-37. doi: 10.1210/me.2014-1206.

13.

Cyclin A2 and its associated kinase activity are required for optimal induction of progesterone receptor target genes in breast cancer cells.

Moore NL, Edwards DP, Weigel NL.

J Steroid Biochem Mol Biol. 2014 Oct;144 Pt B:471-82. doi: 10.1016/j.jsbmb.2014.09.009. Epub 2014 Sep 16.

14.

AR collaborates with ERα in aromatase inhibitor-resistant breast cancer.

Rechoum Y, Rovito D, Iacopetta D, Barone I, Andò S, Weigel NL, O'Malley BW, Brown PH, Fuqua SA.

Breast Cancer Res Treat. 2014 Oct;147(3):473-85. doi: 10.1007/s10549-014-3082-8. Epub 2014 Sep 2.

15.

Androgen receptor and its splice variant, AR-V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells.

Krause WC, Shafi AA, Nakka M, Weigel NL.

Int J Biochem Cell Biol. 2014 Sep;54:49-59. doi: 10.1016/j.biocel.2014.06.013. Epub 2014 Jul 4.

16.

The prostate cancer TMPRSS2:ERG fusion synergizes with the vitamin D receptor (VDR) to induce CYP24A1 expression-limiting VDR signaling.

Kim JS, Roberts JM, Bingman WE 3rd, Shao L, Wang J, Ittmann MM, Weigel NL.

Endocrinology. 2014 Sep;155(9):3262-73. doi: 10.1210/en.2013-2019. Epub 2014 Jun 13.

17.

Metabolomic profiling identifies biochemical pathways associated with castration-resistant prostate cancer.

Kaushik AK, Vareed SK, Basu S, Putluri V, Putluri N, Panzitt K, Brennan CA, Chinnaiyan AM, Vergara IA, Erho N, Weigel NL, Mitsiades N, Shojaie A, Palapattu G, Michailidis G, Sreekumar A.

J Proteome Res. 2014 Feb 7;13(2):1088-100. doi: 10.1021/pr401106h. Epub 2013 Dec 31.

18.

Androgen receptors in hormone-dependent and castration-resistant prostate cancer.

Shafi AA, Yen AE, Weigel NL.

Pharmacol Ther. 2013 Dec;140(3):223-38. doi: 10.1016/j.pharmthera.2013.07.003. Epub 2013 Jul 13. Review.

PMID:
23859952
19.

Phosphorylation: a fundamental regulator of steroid receptor action.

Treviño LS, Weigel NL.

Trends Endocrinol Metab. 2013 Oct;24(10):515-24. doi: 10.1016/j.tem.2013.05.008. Epub 2013 Jul 6. Review.

20.

The requirement for p42/p44 MAPK activity in progesterone receptor-mediated gene regulation is target gene-specific.

Treviño LS, Bingman WE 3rd, Edwards DP, Nl W.

Steroids. 2013 Jun;78(6):542-7. doi: 10.1016/j.steroids.2012.12.014. Epub 2013 Feb 1.

21.

Androgen receptor splice variants are resistant to inhibitors of Hsp90 and FKBP52, which alter androgen receptor activity and expression.

Shafi AA, Cox MB, Weigel NL.

Steroids. 2013 Jun;78(6):548-54. doi: 10.1016/j.steroids.2012.12.013. Epub 2013 Feb 1.

22.
23.

Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression.

He S, Zhang C, Shafi AA, Sequeira M, Acquaviva J, Friedland JC, Sang J, Smith DL, Weigel NL, Wada Y, Proia DA.

Int J Oncol. 2013 Jan;42(1):35-43. doi: 10.3892/ijo.2012.1698. Epub 2012 Nov 14.

24.

A standards-based, peer-reviewed teaching award to enhance a medical school's teaching environment and inform the promotions process.

Searle NS, Teal CR, Richards BF, Friedland JA, Weigel NL, Hernandez RA, Lomax JW, Coburn M, Nelson EA.

Acad Med. 2012 Jul;87(7):870-6. doi: 10.1097/ACM.0b013e3182584130.

PMID:
22622222
25.

Regulation of progesterone receptor activity by cyclin dependent kinases 1 and 2 occurs in part by phosphorylation of the SRC-1 carboxyl-terminus.

Moore NL, Weigel NL.

Int J Biochem Cell Biol. 2011 Aug;43(8):1157-67. doi: 10.1016/j.biocel.2011.04.009. Epub 2011 Apr 21.

26.

Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer.

Hodgson MC, Shao LJ, Frolov A, Li R, Peterson LE, Ayala G, Ittmann MM, Weigel NL, Agoulnik IU.

Cancer Res. 2011 Jan 15;71(2):572-82. doi: 10.1158/0008-5472.CAN-10-2314. Epub 2011 Jan 11.

27.

1α,25-dihydroxyvitamin D3 inhibits C4-2 prostate cancer cell growth via a retinoblastoma protein (Rb)-independent G1 arrest.

Washington MN, Kim JS, Weigel NL.

Prostate. 2011 Jan 1;71(1):98-110. doi: 10.1002/pros.21226.

28.

1{alpha},25-Dihydroxyvitamin D3 inhibits growth of VCaP prostate cancer cells despite inducing the growth-promoting TMPRSS2:ERG gene fusion.

Washington MN, Weigel NL.

Endocrinology. 2010 Apr;151(4):1409-17. doi: 10.1210/en.2009-0991. Epub 2010 Feb 10.

29.

Partial agonist activity of the progesterone receptor antagonist RU486 mediated by an amino-terminal domain coactivator and phosphorylation of serine400.

Wardell SE, Narayanan R, Weigel NL, Edwards DP.

Mol Endocrinol. 2010 Feb;24(2):335-45. doi: 10.1210/me.2008-0081. Epub 2009 Dec 11.

30.

Steroid receptor phosphorylation: Assigning function to site-specific phosphorylation.

Ward RD, Weigel NL.

Biofactors. 2009 Nov-Dec;35(6):528-36. doi: 10.1002/biof.66. Review.

31.

Parathyroid hormone-related protein regulates cell survival pathways via integrin alpha6beta4-mediated activation of phosphatidylinositol 3-kinase/Akt signaling.

Bhatia V, Mula RV, Weigel NL, Falzon M.

Mol Cancer Res. 2009 Jul;7(7):1119-31. doi: 10.1158/1541-7786.MCR-08-0568. Epub 2009 Jul 7.

32.

EB1089 inhibits the parathyroid hormone-related protein-enhanced bone metastasis and xenograft growth of human prostate cancer cells.

Bhatia V, Saini MK, Shen X, Bi LX, Qiu S, Weigel NL, Falzon M.

Mol Cancer Ther. 2009 Jul;8(7):1787-98. doi: 10.1158/1535-7163.MCT-09-0064. Epub 2009 Jul 7.

33.

Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells.

De Amicis F, Thirugnansampanthan J, Cui Y, Selever J, Beyer A, Parra I, Weigel NL, Herynk MH, Tsimelzon A, Lewis MT, Chamness GC, Hilsenbeck SG, Andò S, Fuqua SA.

Breast Cancer Res Treat. 2010 May;121(1):1-11. doi: 10.1007/s10549-009-0436-8. Epub 2009 Jun 17.

34.

Coactivator selective regulation of androgen receptor activity.

Agoulnik IU, Weigel NL.

Steroids. 2009 Aug;74(8):669-74. doi: 10.1016/j.steroids.2009.02.007. Epub 2009 Mar 9.

35.

1Alpha,25-dihydroxyvitamin D3 reduces c-Myc expression, inhibiting proliferation and causing G1 accumulation in C4-2 prostate cancer cells.

Rohan JN, Weigel NL.

Endocrinology. 2009 May;150(5):2046-54. doi: 10.1210/en.2008-1395. Epub 2009 Jan 22.

36.

Target gene-specific regulation of androgen receptor activity by p42/p44 mitogen-activated protein kinase.

Agoulnik IU, Bingman WE 3rd, Nakka M, Li W, Wang Q, Liu XS, Brown M, Weigel NL.

Mol Endocrinol. 2008 Nov;22(11):2420-32. doi: 10.1210/me.2007-0481. Epub 2008 Sep 11.

37.

Androgen receptor coactivators and prostate cancer.

Agoulnik IU, Weigel NL.

Adv Exp Med Biol. 2008;617:245-55. doi: 10.1007/978-0-387-69080-3_23. Review. No abstract available.

PMID:
18497048
38.

PTHrP contributes to the anti-proliferative and integrin alpha6beta4-regulating effects of 1,25-dihydroxyvitamin D(3).

Shen X, Mula RV, Li J, Weigel NL, Falzon M.

Steroids. 2007 Dec;72(14):930-8. Epub 2007 Aug 15.

39.

Interactions between vitamin D and androgen receptor signaling in prostate cancer cells.

Weigel NL.

Nutr Rev. 2007 Aug;65(8 Pt 2):S116-7. Review. No abstract available.

PMID:
17867385
40.

Constitutively active FOXO1a and a DNA-binding domain mutant exhibit distinct co-regulatory functions to enhance progesterone receptor A activity.

Rudd MD, Gonzalez-Robayna I, Hernandez-Gonzalez I, Weigel NL, Bingman WE 3rd, Richards JS.

J Mol Endocrinol. 2007 Jun;38(6):673-90.

PMID:
17556536
41.

Steroid receptor phosphorylation: a key modulator of multiple receptor functions.

Weigel NL, Moore NL.

Mol Endocrinol. 2007 Oct;21(10):2311-9. Epub 2007 May 29. Review.

PMID:
17536004
42.

Kinases and protein phosphorylation as regulators of steroid hormone action.

Weigel NL, Moore NL.

Nucl Recept Signal. 2007 May 17;5:e005. Review.

43.

Cyclins, cyclin dependent kinases, and regulation of steroid receptor action.

Weigel NL, Moore NL.

Mol Cell Endocrinol. 2007 Feb;265-266:157-61. Epub 2007 Jan 5. Review.

44.

Cyclin dependent kinase 2 and the regulation of human progesterone receptor activity.

Moore NL, Narayanan R, Weigel NL.

Steroids. 2007 Feb;72(2):202-9. Epub 2007 Jan 4. Review.

45.

International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors.

Lu NZ, Wardell SE, Burnstein KL, Defranco D, Fuller PJ, Giguere V, Hochberg RB, McKay L, Renoir JM, Weigel NL, Wilson EM, McDonnell DP, Cidlowski JA.

Pharmacol Rev. 2006 Dec;58(4):782-97. Review. No abstract available.

PMID:
17132855
46.

Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer.

Agoulnik IU, Vaid A, Nakka M, Alvarado M, Bingman WE 3rd, Erdem H, Frolov A, Smith CL, Ayala GE, Ittmann MM, Weigel NL.

Cancer Res. 2006 Nov 1;66(21):10594-602.

47.

Androgen receptor action in hormone-dependent and recurrent prostate cancer.

Agoulnik IU, Weigel NL.

J Cell Biochem. 2006 Oct 1;99(2):362-72. Review.

PMID:
16619264
48.

Quantifying effects of ligands on androgen receptor nuclear translocation, intranuclear dynamics, and solubility.

Marcelli M, Stenoien DL, Szafran AT, Simeoni S, Agoulnik IU, Weigel NL, Moran T, Mikic I, Price JH, Mancini MA.

J Cell Biochem. 2006 Jul 1;98(4):770-88.

PMID:
16440331
49.

Akt phosphorylates and suppresses the transactivation of retinoic acid receptor alpha.

Srinivas H, Xia D, Moore NL, Uray IP, Kim H, Ma L, Weigel NL, Brown PH, Kurie JM.

Biochem J. 2006 May 1;395(3):653-62.

50.

Dual roles for the phosphatase PPM1D in regulating progesterone receptor function.

Proia DA, Nannenga BW, Donehower LA, Weigel NL.

J Biol Chem. 2006 Mar 17;281(11):7089-101. Epub 2005 Dec 13.

Supplemental Content

Loading ...
Support Center